In vitro antimicrobial activity of imipenem plus amikacin or polymyxin B against carbapenem-resistant Pseudomonas aeruginosa isolates
CM Wilhelm, LS Nunes, AF Martins, AL Barth - Diagnostic microbiology and …, 2018 - Elsevier
The aim of this study was to evaluate the antimicrobial activity of imipenem plus amikacin or
polymyxin B against six carbapenem-resistant P. aeruginosa by time-kill assay. Synergism …
polymyxin B against six carbapenem-resistant P. aeruginosa by time-kill assay. Synergism …
In vitro Pharmacodynamics and PK/PD in Animals
In the last decade, considerable advancements have been made to identify the
pharmacokinetic/pharmacodynamic (PK/PD) index that defines the antimicrobial activity of …
pharmacokinetic/pharmacodynamic (PK/PD) index that defines the antimicrobial activity of …
Decoding (patho-) physiology of the lung by advanced in vitro models for developing novel anti-infectives therapies
CV Montefusco-Pereira… - Drug Discovery …, 2021 - Elsevier
In 2017, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) identified
lower respiratory tract infections as the 4 th leading causes for early death worldwide …
lower respiratory tract infections as the 4 th leading causes for early death worldwide …
A novel chemical biology approach for mapping of polymyxin lipopeptide antibody binding epitopes
T Velkov, B Yun, EK Schneider, MAK Azad… - ACS infectious …, 2016 - ACS Publications
Polymyxins B and E (ie, colistin) are a family of naturally occurring lipopeptide antibiotics
that are our last line of defense against multidrug resistant (MDR) Gram-negative pathogens …
that are our last line of defense against multidrug resistant (MDR) Gram-negative pathogens …
[PDF][PDF] Effect of antibiotics combination and comparison of methods for detection of synergism in multiresistant Gram-negative bacteria
GC Leite, LVP Neto, JJ Gaudereto… - J. Infect. Dis. Ther, 2015 - Citeseer
Background: Because of the rapid spread of antimicrobial resistance and the slow
development of novel antimicrobials, Gram-negative infections treatments are challenging …
development of novel antimicrobials, Gram-negative infections treatments are challenging …
Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical …
X Liu, C Huang, PJ Bergen, J Li, J Zhang… - Journal of Zhejiang …, 2023 - Springer
Polymyxin B, which is a last-line antibiotic for extensively drug-resistant Gram-negative
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …
Antimicrobial combination effects against multidrug‐resistant Acinetobacter baumannii and Pseudomonas aeruginosa strains: A cross‐sectional study
Abstract Background and Aims Emergence of multidrug resistance in non‐fermenting Gram‐
negative bacilli is a threat to public health. Combination therapy is a strategy for the …
negative bacilli is a threat to public health. Combination therapy is a strategy for the …
Polymyxin pharmacokinetics and pharmacodynamics
Polymyxin B and E (the latter more commonly known as colistin) were originally introduced
into clinical medicine in the late 1950s for the treatment of infections caused by gram …
into clinical medicine in the late 1950s for the treatment of infections caused by gram …
Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates
MM Montero, S Domene-Ochoa… - Microbiology …, 2022 - Am Soc Microbiol
The aim of this study was to compare the efficacy of intermittent (1-h), extended (4-h), and
continuous ceftolozane-tazobactam (C/T) infusion against three extensively drug-resistant …
continuous ceftolozane-tazobactam (C/T) infusion against three extensively drug-resistant …
多黏菌素B 治疗药物监测专家共识: 中国药理学会治疗药物监测研究专业委员会及上海市医学会感染与化疗专科分会发起制定
X LIU, C HUANG, PJ BERGEN, J LI… - Journal of Zhejiang …, 2023 - jzus.zju.edu.cn
多黏菌素B 是治疗广泛耐药革兰氏阴性细菌感染的最后" 一道防线", 但因剂量限制性肾毒性及低
剂量可能出现治疗失败和耐药性, 临床上迫切需要通过治疗药物监测(TDM) 优化其使用 …
剂量可能出现治疗失败和耐药性, 临床上迫切需要通过治疗药物监测(TDM) 优化其使用 …